

Ethnic Differences Affect Metabolic Screening

BY PATRICE WENDLING

CHICAGO — Ethnic differences in dyslipidemia should be factored into screening programs for metabolic syndrome, Dr. Anne E. Sumner said at a meeting sponsored by the International Society on Hypertension in Blacks.

Atherogenic dyslipidemia, one of the key criteria used to identify metabolic syndrome, is present more often in whites and Hispanics than in blacks, who tend to have normal triglycerides and low HDL cholesterol levels.

“This challenges the conventional thinking about the interrelationship of triglycerides and HDL,” she said.

A recent unpublished study using National Health and Nutrition Examination Survey (NHANES) data from 1999 to 2004 showed that the frequency of increased triglycerides was significantly lower in blacks than whites and Hispanics, even after adjustment for sex and body mass index, said Dr. Sumner of the National Institute of Diabetes and Digestive and Kidney Diseases.

An earlier study she published showed that blacks are more likely than whites or Mexican Americans to be insulin resistant and to have triglyceride levels below threshold values used to define enlarged-waist elevated-triglyceride syndrome, overweight lipid syndrome, or hypertriglyceridemic waist syndrome (Atherosclerosis 2008;196:696-703).

The three syndromes—proposed as better predictors of the onset of coronary artery disease and type 2 diabetes, compared with metabolic syndrome—were defined based on data from populations that were predominantly non-Hispanic white.

“From a public health point of view, the absence of elevated triglycerides in blacks does not mean the absence of risk,” she said. “We need then to beware of screening programs that use triglycerides to diagnose risk.

“Isolated low HDL is a manifestation of insulin resistance and represents a cardiovascular disease risk and therefore should be treated.”

She noted that three studies have shown the benefits of treating low HDL—the Helsinki Heart Study; the Veterans Affairs High-Density Lipoprotein Intervention Trial, which had excellent representation of African Americans; and the INTERHEART Africa Study, conducted in sub-Saharan Africa.

Still, the latest report from the American Heart Association shows that death rates from cardiovascular disease are highest among blacks, despite an overall decline of 26.4% from 1995 to 2005. The death rate from CVD in 2005 was 278.9 per 100,000 persons overall, but was 438.4/100,000 in black men and 319.7/100,000 in black women (Circulation 2009;119:e21-181).

Several factors may contribute to the dyslipidemia pattern seen in blacks, explained Dr. Sumner, who stressed that her views are not those of the U.S. government or the National Institutes of

Health. Blacks have higher lipoprotein lipase levels and lower apolipoprotein CIII levels, which promotes elevated triglycerides. Blacks also have less visceral adipose tissue and intrahepatic fat, which results in less production of very-low-density lipoprotein, a major carrier of triglycerides.


Dr. Sumner noted that there is a push underway worldwide to use hypertriglyceridemic waist syndrome to pre-

dict cardiovascular risk. The test is cheaper to perform than the metabolic triad, requiring only the simple variables of waist circumference of 90 cm or more in men and at least 85 cm in women and a plasma triglyceride level of 177 mg/dL or more.

This approach works in whites, but not in blacks, Dr. Sumner said. She cited unpublished results from ongoing research in 120 overweight, obese, or pre-

diabetic African Americans showing that 40 had the metabolic triad, but only 3 had a triglyceride level over 177 mg/dL. She suggested that prospective studies are needed to explore whether a reformulation of metabolic syndrome parameter thresholds might optimize risk identification in populations of African ancestry.

Dr. Sumner disclosed no conflicts of interest or study support. ■



A critical measure of patient health: ABDOMINAL AORTIC DIAMETER

BladderScan® BVI 9600 with a brief onboard video tutorial to train staff.

Introducing the BladderScan® BVI 9600 with AortaScan™ mode.

Every year more patients may be at risk for abdominal aortic aneurysm (AAA). Now you can add a critical measure of patient health to your practice.

The BladderScan® BVI 9600 is a portable, noninvasive 3D ultrasound instrument that lets you measure abdominal aortic diameter quickly and accurately.

- Helps physicians identify the presence of AAA
- Easy to use; no sonographer is required
- Exam data can be printed via the onboard printer or transmitted to your computer for an EMR

The BVI 9600 also features a bladder volume mode to measure post-void residual and help assess urinary retention.

How many of your patients are at risk for AAA? Help identify them with the BladderScan® BVI 9600 with AortaScan™ mode.

Call 800.331.2313
or go to verathon.com.
**Visit us at the AAFP Scientific
Assembly, Booth #3244,
Oct. 15-17, Boston MA.**

0900-2637-00-86 901FPN-Ad BladderScan, AortaScan, ScanPoint, and Verathon are trademarks of Verathon Inc. © 2009 Verathon Inc.



BladderScan®
Bladder Volume Instruments
Noninvasive, Accurate, Reliable, Easy to Use

